Management

Jennifer L. GoodPresident and CEO

Jennifer Good is the co-founder of Trevi Therapeutics and serves as a director as well as the Company's President and Chief Executive Officer. Ms. Good has served as the Company’s President and CEO since inception, raising through Series C capital and overseeing the development of Nalbuphine ER into Phase 3 development. Prior to founding Trevi, Ms. Good successfully led the transition of a publicly traded life sciences company, Penwest Pharmaceuticals Co., from a development stage company to generating annual revenues in excess of $50 million with strong profitability. The Company was acquired by its strategic partner in 2010.

Ms. Good received a Bachelor of Business Administration degree with a Concentration in Accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Ms. Good currently serves on the board of Juniper Pharmaceuticals, a publicly traded women’s health therapeutics company, and is a member of Juniper’s Audit and Compensation Committees. In addition, Ms. Good is a board member of the Friedreich's Ataxia Research Alliance (FARA), which is a patient advocacy group advancing treatments for the cure of Friedreich's Ataxia. Ms. Good serves on FARA’s Executive, Business Development and Finance Committees. Ms. Good is also the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community.

Christopher J. Seiter Chief Financial Officer

Christopher Seiter, Trevi’s Chief Financial Officer, has over two decades of experience in the healthcare industry. He most recently served as Chief Financial Officer of Millendo Therapeutics. Mr. Seiter has extensive experience in corporate finance and has advised a wide variety of biopharmaceutical companies through various stages of their life cycles. Prior to transitioning to an operational role, Mr. Seiter served as a Managing Director at Bank of America Merrill Lynch in the healthcare investment banking group. In this capacity, he focused on advising life sciences companies on transactions ranging from equity and debt financings to mergers and acquisitions. He joined Bank of America Merrill Lynch in 1999 and held various roles of increasing responsibility including Head of Life Sciences Investment Banking. Prior to joining Bank of America Merrill Lynch, Mr. Seiter worked in the healthcare investment banking groups at UBS, Dillon Read and Kidder Peabody. Mr. Seiter also served in the U.S. Navy as a Nuclear Submarine Officer for five years.

Mr. Seiter received a B.A. in economics cum laude from the University of Rochester and completed a graduate level program in nuclear engineering at the U.S. Naval Nuclear Power School.

Thomas R. Sciascia, M.D.Chief Medical Officer

Thomas Sciascia, M.D. is the co-founder of Trevi Therapeutics and serves as the Company's Chief Medical Officer. Dr. Sciascia has an extensive background in clinical development and regulatory strategy. Prior to founding Trevi, Dr. Sciascia was the Sr. Vice President of Clinical Development and Regulatory and Chief Medical Officer at Penwest Pharmaceuticals. Prior to working at Penwest, Dr. Sciascia worked at Quintiles, Inc. as a consultant to pharma and biotechnology companies. He also worked as a Medical Director at Transkaryotic Therapeutics. Dr. Sciascia received a Bachelors of Science Degree in Biology at Massachusetts Institute of Technology and a Medical Degree at Columbia University. He is a board certified neurologist licensed to practice medicine in the state of Massachusetts. Dr. Sciascia has numerous issued patents and is the author on several publications.

Helena Brett-Smith, M.D.Chief Development Officer

Helena Brett-Smith, M.D. has more than 25 years of clinical and drug development experience. Dr. Brett-Smit came to Trevi in September, 2017 after a 17-year career at Bristol-Myers Squibb, where she was most recently Vice President and Head of Fibrosis Full Development. Dr. Brett-Smith was deeply involved in the clinical development of Baraclude® for the treatment of Hepatitis B, contributed to the filing of Yervoy®, and to clinical development projects in HIV, Hepatitis C, Idiopathic Pulmonary Fibrosis, and NASH. Prior to joining Bristol-Myers Squibb, Dr. Brett-Smith was Director of the HIV Program and outpatient care center at the Hospital of Saint Raphael in New Haven, CT from 1992 to 2000.

As a clinical drug developer, Dr. Brett-Smith has worked across small molecules and biologics, and across varied therapeutic areas. She has had extensive experience with successful regulatory filings for new therapies in both the US and Europe, with follow-on pediatric indications. Dr. Brett-Smith's Asian experience included projects in China, Japan and Korea.

Dr. Brett-Smith earned her undergraduate degree from Yale University and her MD from Stanford University School of Medicine. She completed her residency in Internal Medicine and a fellowship in Infectious Diseases at the Yale School of Medicine. Dr. Brett-Smith has also lived for 3 years in the Ivory Coast, West Africa working as a Peace Corps volunteer in maternal and infant health.

Senior Leadership

Amale Hawi, PhDSenior VP of CMC

Dr. Amale Hawi is currently Senior VP of CMC, Nonclinical and Clinical Pharmacology at Trevi Therapeutics. Dr. Hawi had served as Senior Vice president of Pharmaceutical Development at Penwest Pharmaceuticals where she oversaw the CMC and DMPK of NCEs. She has more than 25 years of hands-on experience in preformulation, formulation and manufacturing, preclinical and clinical PK from compound selection into registration and has developed innovator and repurposed drugs from concept to commercialization. Her primary interest is the development of an integrated CMC-biopharmaceutical approach to drug product development. Prior to joining Trevi, she collaborated with Trevi as an independent consultant and other Pharmaceutical organizations providing drug development, CMC and Regulatory consulting services across the development cycle.  

Previoulsy, Dr. Hawi spend 12 years at Boehringer Ingelheim Pharmaceuticals where she held several positions of increasing responsibilities in the Pharmaceutics Department and Drug Metabolism and Pharmacokinetics.

Prior to joining the pharmaceutical industry, she was a research assistant professor at the University of Kentucky, College of Pharmacy.  She holds a Ph.D. in Organic Chemistry from the University of London, England and an M.Sc. from the American University in Beirut, Lebanon.

Board of Directors

David Meeker, M.D.Chairman

David Meeker, M.D. has served as a Board advisor to Trevi since inception, and was one of the Company’s original angel investors. Dr. Meeker is the President & CEO of KSQ, a biotech company with a proprietary CRISPRomics drug discovery engine. Utilizing this engine, KSQ is advancing a pipeline of oncology and immunology drug development programs against novel therapeutic nodes. Dr. Meeker was formerly the President and CEO of Genzyme, a Sanofi company, a position he assumed when Genzyme merged with Sanofi in 2011. He was also a member of the executive committee.  

In his career with Genzyme, Dr. Meeker held key positions of increasing responsibility beginning in the R&D organization and subsequently in operating roles, culminating in the position of Chief Operating Officer at the time of the merger. In his most recent role within Sanofi, he headed Sanofi-Genzyme, the specialty care unit with responsibility for Rare Diseases, MS, Oncology and Immunology franchises.

Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He completed his internal medicine training at Harvard’s Beth Israel Hospital and his pulmonary/critical training at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.

Dr. Meeker is also the Chairman of the Board of Rhythm and a member of the board at Myokardia.

Jennifer L. Good

Jennifer Good is the co-founder of Trevi Therapeutics and serves as a director as well as the Company's President and Chief Executive Officer. Ms. Good has served as the Company’s President and CEO since inception, raising through Series C capital and overseeing the development of Nalbuphine ER into Phase 3 development. Prior to founding Trevi, Ms. Good successfully led the transition of a publicly traded life sciences company, Penwest Pharmaceuticals Co., from a development stage company to generating annual revenues in excess of $50 million with strong profitability. The Company was acquired by its strategic partner in 2010.

Ms. Good received a Bachelor of Business Administration degree with a Concentration in Accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Ms. Good currently serves on the board of Juniper Pharmaceuticals, a publicly traded women’s health therapeutics company, and is a member of Juniper’s Audit and Compensation Committees. In addition, Ms. Good is a board member of the Friedreich's Ataxia Research Alliance (FARA), which is a patient advocacy group advancing treatments for the cure of Friedreich's Ataxia. Ms. Good serves on FARA’s Executive, Business Development and Finance Committees. Ms. Good is also the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community.

Ed Mathers

Ed Mathers joined NEA as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Liquidia Technologies, Ra Pharmaceuticals NASDAQ:RARX – Chairman), Rhythm Pharmaceuticals, Envisia Therapeutics, Synlogic, Mirna Therapeutics (NASDAQ:MIRN), Lumos Pharma, Amplyx Pharmaceuticals, Senti Biosciences, Inozyme, and ObsEva (NASDAQ:OBSV).

Previously he was a board member of Lumena (sold to Shire),  Ziarco (sold to Novartis), Motus Therapeutics (sold to Allergan), Plexxikon (sold to Daiichi Sankyo), Intarcia, Satori Pharmaceuticals, Southeast Bio, MedImmune, LLC, and the Biotechnology Industry Organization (BIO).

Prior to joining NEA, Ed most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. In this role, he was a member of the leadership team that executed the sale of the company to AstraZeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor's degree in chemistry from North Carolina State University.

Eran Nadav, PhD

Dr. Eran Nadav is an investor and a biopharma veteran. He has been with the investment firm TPG from 2007 to 2018, serving as Partner and Managing Director at the TPG Biotech fund in San Francisco. During his tenure at TPG, he led pharma and biotech deals across various geographies and stages of development. Currently he serves as Senior Advisor of TPG Biotech.

Prior to TPG, Dr. Nadav was Business Development Director at Eisai in New Jersey, where he evaluated and negotiated licensing and acquisition deals. Previously, Dr. Nadav worked for JJDC, the venture capital subsidiary of Johnson & Johnson. Earlier, he worked for Neurim Pharmaceuticals in a product development role.

Dr. Nadav holds a Ph.D. in Biochemistry, an M.Sc. magna cum laude, a B.Sc. magna cum laude, and an MBA from Tel Aviv University.

Dr. Nadav is currently a board member at Carisma Therapeutics, Fusion Pharmaceuticals, Nutrinia, Trevi Therapeutics, and Tevel Aerobotics Technologies. He is also a member at the Investment Committee of Lagunita Biosciences, a healthcare investment company and incubator. Representing TPG, Dr. Nadav was the lead investor and Chairman of the Board of Ultragenyx Pharmaceutical (Nasdaq: RARE) and Trevi Therapeutics. His other past investments and board roles include Collegium Pharmaceutical (Nasdaq: COLL), JCR Pharmaceuticals (a Japanese biopharma company, TSE: 4552), MacroGenics (Nasdaq: MGNX), ShangPharma (a China based CRO), and Eden Springs / Mey Eden (a leading European provider of workplace drinks solutions). 

Mette Kirsten Agger

Mette Kirstine Agger is a Managing Partner at Lundbeckfonden. Ms. Agger has a broad international experience within biotech / life science covering business development and licensing, management and financing and has been appointed to numerous board positions both in private and public companies.

Mette was previously co-founder and CEO of 7TM Pharma A/S. Prior to founding 7TM Pharma, Mette was part of the management team of NeuroSearch A/S responsible for business development and licensing. She started her career as Patent Agent and has over the years co-founded several biotech companies. Mette Kirstine Agger graduated as Biologist from the University of Copenhagen and has an MBA from Henley Business School.

Mette is also a board member at Cydan Development, Imara, Psioxus, scPharmaceuticals, Thesan Pharmaceuticals and Veloxis.

Michael Heffernan

Michael Heffernan has over 25 years of experience in the pharmaceutical and related healthcare industries. He is Founder, President and CEO of Collegium Pharmaceutical (NASDAQ: COLL), a specialty pharmaceutical company that is developing abuse deterrent products for the treatment of chronic pain and other disorders. He was previously the founder, President and CEO of Onset Dermatologics, a dermatology focused company that was spun out of Collegium to create PreCision Dermatology and was later sold to Valeant (2014). Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp and later served as President and CEO of PhyMatrix.

Michael began his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been an advisor and Investor in a number of biopharma, medical device and healthcare services companies. His recent board memberships include: TyRx (sold to Medtronic), Cornerstone Therapeutics (sold to Chiesi), PreCision Dermatology (sold to Valeant), and Ocata Therapeutics (sold to Astellas). Michael is currently Chairman of the board of Veloxis Pharmaceuticals (OMX: VELO) and a member of the board of Keryx Biopharmaceuticals (NASDAQ: KERX). Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.

Anne VanLent

Ms. VanLent joins Trevi’s Board with over 30 years of experience working with emerging growth life sciences companies. She founded and serves as President of AMV Advisors, an advisory firm that provides strategic and management consulting services to emerging growth companies in the life sciences industry. Ms. VanLent has held senior executive and financial leadership roles with Barrier Therapeutics, Inc., Sarnoff Corporation (a division of SRI International), Trophix Pharmaceuticals, Inc. and The Liposome Company, Inc. She is currently a member of the board of directors and audit chair of both Vaxart, Inc. and Advanced Genetic Technologies, Inc. and has held prior board seats for Ocera, Novelion, Onconova, Integra Life Sciences, Penwest Pharmaceuticals, and several private companies. Ms. VanLent received a B.A. in Physics from Mount Holyoke College.

Annie Mitsak, PhD

Dr. Annie Mitsak is on the investment team at Omega Funds, which she joined in October 2015. She focuses on private company investing, particularly in the areas of oncology, inflammatory diseases and technology platforms.

 

Prior to joining Omega, Dr. Mitsak spent three years at MIT’s Technology Licensing Office as a licensing associate and associate licensing officer, where she managed a portfolio of drug delivery and biotechnology inventions. Dr. Mitsak also worked as an independent consultant for Nelsen Biomedical, where she performed market analyses and advised clients on partnering and market entry strategies. Dr. Mitsak earned her Ph.D. in Biomedical Engineering from the University of Michigan and a BS in Biomedical Engineering from the University of Virginia.

Founder's Story

Enter a founder's story here.